LRMR Key Statistics, Chart & Performance
The current stock price of LRMR is 3.92 USD. In the past month the price increased by 15.98%. In the past year, price decreased by -2.24%.
LRMR Latest News, Press Relases and Analysis
LRMR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.07 | 401.99B | ||
| AMGN | AMGEN INC | 14.87 | 175.17B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 79.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.65 | 51.72B | ||
| INSM | INSMED INC | N/A | 42.00B | ||
| NTRA | NATERA INC | N/A | 31.52B | ||
| BIIB | BIOGEN INC | 10.5 | 25.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.96 | 21.54B | ||
| INCY | INCYTE CORP | 15.36 | 19.37B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About LRMR
Company Profile
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 65 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Company Info
LARIMAR THERAPEUTICS INC
Three Bala Plaza East. Suite 506
Bala Cynwyd PENNSYLVANIA 19004 US
CEO: Carole Ben-Maimon
Employees: 65
Phone: 18445119056
LARIMAR THERAPEUTICS INC / LRMR FAQ
What does LRMR do?
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 65 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
What is the stock price of LARIMAR THERAPEUTICS INC today?
The current stock price of LRMR is 3.92 USD. The price decreased by -3.21% in the last trading session.
Does LRMR stock pay dividends?
LRMR does not pay a dividend.
How is the ChartMill rating for LARIMAR THERAPEUTICS INC?
LRMR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists LRMR stock?
LRMR stock is listed on the Nasdaq exchange.
Can you provide the market cap for LARIMAR THERAPEUTICS INC?
LARIMAR THERAPEUTICS INC (LRMR) has a market capitalization of 335.51M USD. This makes LRMR a Small Cap stock.
When does LARIMAR THERAPEUTICS INC (LRMR) report earnings?
LARIMAR THERAPEUTICS INC (LRMR) will report earnings on 2026-03-23, after the market close.
LRMR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LRMR. When comparing the yearly performance of all stocks, LRMR is a bad performer in the overall market: 70.74% of all stocks are doing better.
LRMR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LRMR. While LRMR seems to be doing ok healthwise, there are quite some concerns on its profitability.
LRMR Financial Highlights
Over the last trailing twelve months LRMR reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS decreased by -67.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.46% | ||
| ROE | -94.94% | ||
| Debt/Equity | 0 |
LRMR Forecast & Estimates
18 analysts have analysed LRMR and the average price target is 16.97 USD. This implies a price increase of 332.89% is expected in the next year compared to the current price of 3.92.